Georgina Long, ESMO 2022: CheckMate 915 study – The use of ctDNA as a biomarker for predicting outcomes for adjuvant melanoma
Access all of the content
In patients with resectable melanoma, circulating tumor DNA (ctDNA) detection post-resection may be useful to inform disease state and recurrence risk. Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss CheckMate 915 study and what it taught us about the use of nivolumab plus ipilumab in the adjuvant treatment of melanoma, and the use of ctDNA as a biomarker for combined analyses predicting outcomes for adjuvant melanoma.
The abstract entitled ‘Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIBD/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)‘ Abstract LBA31, was presented at European Society for Medical Oncology (ESMO) 2022.
Watch Dr Georgina Long’s top highlights in melanoma at ESMO 2022
Questions:
- What is known about the clinical utility of circulating tumour DNA in patients with resectable melanoma, and what did the CheckMate 915 study show? (0:11)
- What were the aims and designs of the analysis of the CheckMate 915 study? (2:08)
- What can we conclude about the usefulness of ctDNA as a biomarker, and what further research is needed? (3:01)
Disclosures: Georgina Long has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
